Pembrolizumab for the treatment of colorectal cancer

References

• GLOBOCAN. International agency for research on cancer 2018. 2018.
   Google Scholar
• American Cancer Society. Cancer facts & figures 2019. Atlanta (GA): American Cancer Society; 2019.
   Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193.
   PubMed Web of Science ®Google Scholar
• Douillard JY. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. Oncology (Williston Park). 2000;14(12 Suppl 14):51–55.
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the GruppoOncologicoNordOvest. J Clin Oncol. 2007;25(13):1670–1676.
   PubMed Web of Science ®Google Scholar
• deGramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–2019.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne C-H, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–2019.
   PubMed Web of Science ®Google Scholar
• Grothey A, Cutsem EV, Sobrero A, et al. Regorafenibmonotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13(10):993–1001.
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Barbolini M, Spallanzani A, et al. The evolving role of microsatellite instability in colorectal cancer: a review. Cancer Treat Rev. 2016;51:19–26.
   PubMed Web of Science ®Google Scholar
• Hendriks YM, de Jong AE, Morreau H, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin. 2006;56(4):213–225.
   PubMed Web of Science ®Google Scholar
• Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–1860.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993;104(5):1535–1549.
   PubMed Web of Science ®Google Scholar
• Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13(13):3831–3839.
   PubMed Web of Science ®Google Scholar
• Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012;104(21):1635–1646.
   PubMedGoogle Scholar
• Popat S, Hubner R, Houlston RS, et al. Systematic review of microsatellite instability and colorectal cancer prognosis. JClinOncol. 2005;23(3):609–618.
   Google Scholar
• Greenson JK, Bonner JD, Ben-Yzhak O, et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol. 2003;27:563–570.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698–711.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• Sun H-L, Zhou X, Xue Y-F, et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol. 2012 Jul 7;18(25):3303–3309.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182–1191.
   PubMed Web of Science ®Google Scholar
• Morse MA, Overman MJ, Hartman L, et al. Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Oncologist. 2019 Jan 29;24:1453–1461.
   PubMed Web of Science ®Google Scholar
• Eugène J, Jouand N, Ducoin K, et al. The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression. Mod Pathol. 2019 Aug 13.
   PubMedGoogle Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206.
   PubMed Web of Science ®Google Scholar
• Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1(3):207–216.
   PubMed Web of Science ®Google Scholar
• Rayner E, van Gool IC, Palles C, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 2016;16(2):71–81.
   PubMed Web of Science ®Google Scholar
• Fabrizio DA, George TJ, Jr, Dunne RF, et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol. 2018;9(4):610–617.
   PubMed Web of Science ®Google Scholar
• Muzny D, Bainbridge M, Chang K. et al. Cancer genome atlas network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337.
   PubMed Web of Science ®Google Scholar
• Bourdais R, Rousseau B, Pujals A, et al. Polymerase proofreading domain mutations: new opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Crit Rev OncolHematol. 2017;113:242–248.
   PubMed Web of Science ®Google Scholar
• Gong J, Wang C, Lee, PP, et al. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Compr Cancer Network. 2017;15(2):142–147.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018 Feb 22;554(7693):538–543.
   PubMed Web of Science ®Google Scholar
• Roelands J, Kuppen P, Vermeulen L, et al. Immunogenomic classification of colorectal cancer and therapeutic implications. Int J Mol Sci. 2017;18:10.
   Web of Science ®Google Scholar
• Becht E, de Reyniès A, Giraldo NA, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22(16):4057–4066.
   PubMed Web of Science ®Google Scholar
• Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22–32.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I Study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–4293.
   PubMed Web of Science ®Google Scholar
• Wang M, Guo L, Xia F. Safety and efficacy profile of Pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Des Devel Ther. 2017;11:2851–2860.
   PubMed Web of Science ®Google Scholar
• Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv119–iv142.
   PubMedGoogle Scholar
• O’Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12):e0189848.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. NEngl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Le DT, Yoshino T, Jäger D, et al. KEYNOTE-164: phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. J Clin Oncol. 2016;34(4_suppl):TPS787–TPS787.
   Web of Science ®Google Scholar
• Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470–1478.
   Google Scholar
• Le DT, Kavan P, Kim TW, et al. KEYNOTE-164: pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. J Clin Oncol. 2018;36(suppl):3514.
   Google Scholar
• Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Le DT, Yoshino T, et al. KEYNOTE-177: phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC). J Clin Oncol. 2018;36(4_suppl):TPS877–TPS877.
   Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436–443.
   PubMed Web of Science ®Google Scholar
• Shahda S, Noonan AM, Bekaii-Saab TS, et al. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. J Clin Oncol. 2017;35(15_suppl):3541.
   Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012 Mar 22;12(4):237–251.
   PubMed Web of Science ®Google Scholar
• Dechant M, Weisner W, Berger S, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 2008 Jul 1;68(13):4998–5003.
   PubMed Web of Science ®Google Scholar
• Omaya T, Ran S, Ishida T, et al. ascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol. 1998 Feb 1;160(3):1224–1232.
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015 Feb 9;212(2):139–148.
   PubMed Web of Science ®Google Scholar
• Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003 Jun 15;101(12):4878–4886.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Powderly JD, Lieu CH, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33(3_suppl):704.
   Google Scholar
• Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013 Jul;12(7):1322–1331.
   PubMed Web of Science ®Google Scholar
• Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol. 2019;37(15_suppl):2522.
   Web of Science ®Google Scholar
• Shinozaki E, Kawazoe A, Kuboki Y, et al. Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP study): EPOC1503. J Clin Oncol. 2018;36(15_suppl):3530.
   Google Scholar
• Azad NS, Shirai K, McRee AJ, et al. ENCORE 601: a phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer. J Clin Oncol. 2018;36(15_suppl):3557.
   Web of Science ®Google Scholar
• Chajon E, Castelli J, Marsiglia H, et al. The synergistic effect of radiotherapy and immunotherapy: a promising but notsimple partnership. Crit Rev Oncol Hematol. 2017;111:124–132.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Sun W, Bahary N, et al. Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer. J Clin Oncol. 2017;35(15_suppl):3054.
   Google Scholar
• Yarchoan M, Ferguson AK, Durham JN, et al. A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer. J Clin Oncol. 2019;37(4_suppl):563.
   Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Van den Berg JG, et al. LBA37_PR neoadjuvantipilimumab plus nivolumab in early stage colon cancer. Ann Oncol. 2018 Oct;29(suppl_8):mdy424.047.
   Google Scholar